Related Experiment Videos

Common nonsense mutations in RAD52

D W Bell1, D C Wahrer, D H Kang

  • 1Center for Cancer Risk Analysis, Massachusetts General Hospital Cancer Center, and Harvard Medical School, Charlestown 02129, USA.

Cancer Research
|August 27, 1999
PubMed

Insights

Researchers investigated RAD51, RAD52, and RAD54 genes for mutations in breast cancer. They found no evidence that these DNA repair genes are mutated in human breast cancer, suggesting they are not a primary target in this disease.

Area of Science:

  • Genetics
  • Molecular Biology
  • Cancer Research

Background:

  • Homologous recombination is crucial for repairing double-strand DNA breaks.
  • RAD51, RAD52, and RAD54 proteins are key players in this DNA repair pathway.
  • BRCA1 and BRCA2 breast cancer susceptibility genes interact with RAD proteins, suggesting a functional link.

Purpose of the Study:

  • To investigate RAD51, RAD52, and RAD54 genes for germ-line and somatic mutations in breast cancer.
  • To determine if these DNA repair genes are mutated in early-onset breast cancer and cell lines.
  • To assess the potential role of RAD gene mutations in breast cancer development.

Main Methods:

  • Screening of RAD51, RAD52, and RAD54 genes for germ-line mutations in 100 early-onset breast cancer cases.
  • Analysis of RAD genes for somatic mutations in 15 human breast cancer cell lines.
  • Comparison of mutation frequencies with a healthy control population.

Main Results:

  • Two heterozygous premature stop codon mutations (Ser346ter, Tyr415ter) were found in RAD52 germ-line alleles in 5% of breast cancer cases and 8% of controls.
  • A rare germ-line missense mutation was identified in RAD54; no variants were found in RAD51.
  • No somatic mutations in RAD51, RAD52, or RAD54 were detected in breast cancer cell lines.

Conclusions:

  • RAD51, RAD52, and RAD54 are not significantly mutated in human breast cancer, despite their role in DNA repair and association with BRCA genes.
  • The identified RAD52 mutations are common in the general population and do not increase breast cancer risk.
  • These findings suggest that RAD51, RAD52, and RAD54 are unlikely to be primary targets for mutations in breast cancer.

Related Concept Videos